Hemorrhagic Shock and Fluid Resuscitation

Hemorrhagic shock is a state of inadequate tissue perfusion caused by acute blood loss, in which oxygen delivery falls below the demands of the tissues. Fluid resuscitation refers to the strategies used to restore circulating volume and oxygen-carrying capacity while bleeding is brought under control, and contemporary practice emphasizes balanced blood-product transfusion over large volumes of crystalloid.

Definition

Hemorrhagic shock is circulatory failure resulting from acute loss of blood volume sufficient to compromise tissue perfusion and oxygen delivery; fluid resuscitation is the restoration of perfusion and oxygen-carrying capacity, increasingly achieved with balanced blood products alongside definitive hemorrhage control.

Scope

This entry covers the pathophysiology of blood loss and the lethal triad, the recognition of hemorrhagic shock, and the principles that distinguish modern resuscitation (restrained fluids before control, balanced transfusion, and antifibrinolytic therapy) from older high-volume crystalloid approaches. It treats resuscitation as a reference topic and does not provide dosing, transfusion thresholds, or individualized management.

Core questions

• How does acute blood loss produce shock and the self-reinforcing lethal triad?
• Why has practice moved from large-volume crystalloid toward restrained, blood-product-based resuscitation?
• What is the rationale for transfusing plasma, platelets, and red cells in balanced ratios?
• What role does antifibrinolytic therapy play in bleeding trauma patients?

Key concepts

• Tissue hypoperfusion and oxygen debt
• The lethal triad: hypothermia, acidosis, coagulopathy
• Trauma-induced coagulopathy
• Permissive hypotension / restrained resuscitation
• Balanced (1:1:1) blood-product transfusion
• Massive transfusion protocol
• Antifibrinolytic therapy
• Damage-control resuscitation

Mechanisms

Acute blood loss reduces preload and cardiac output, lowering oxygen delivery and forcing tissues toward anaerobic metabolism, which generates lactate and metabolic acidosis. Acidosis and hypothermia impair the coagulation cascade and platelet function, while ongoing bleeding consumes and dilutes clotting factors, producing trauma-induced coagulopathy that worsens hemorrhage. This interaction of hypothermia, acidosis, and coagulopathy is the lethal triad. Modern resuscitation seeks to interrupt the cycle by limiting crystalloid (which dilutes clotting factors and may dislodge clot when given before control), transfusing blood components in balanced proportions to replace what is lost, and using antifibrinolytic therapy to reduce clot breakdown, while bleeding is controlled surgically or by interventional radiology.

Clinical relevance

Hemorrhage is a leading cause of early, potentially preventable death after injury, so the principles of recognizing shock and resuscitating with balanced blood products are central to trauma care and to reading the trauma literature. This entry describes those principles for reference and orientation; it is not a protocol, and decisions about fluids, transfusion, and medications require clinical judgement and institutional guidelines.

Epidemiology

Hemorrhage accounts for a large share of early in-hospital trauma deaths and of potentially survivable battlefield deaths. Severity ranges from compensated blood loss with preserved blood pressure to profound shock; outcomes worsen with delay to hemorrhage control and with established coagulopathy.

History

Trauma resuscitation in the late twentieth century relied heavily on early high-volume crystalloid. The Bickell trial (1994) challenged immediate aggressive fluids in penetrating torso injury, and subsequent military and civilian experience shifted practice toward damage-control resuscitation: restrained fluids, balanced blood-product transfusion, and hemorrhage control. The CRASH-2 trial (2010) then established a survival benefit from early tranexamic acid in bleeding trauma patients, and the PROPPR trial (2015) examined balanced transfusion ratios.

Debates

What is the optimal blood-product transfusion ratio?

The PROPPR trial did not show a significant difference in the primary mortality endpoints between 1:1:1 and 1:1:2 ratios but found patients in the 1:1:1 group achieved hemostasis more often and had fewer deaths from exsanguination, leaving the precise optimal ratio and approach a continuing discussion.

How restrictive should pre-control resuscitation be?

Restrained or permissive-hypotension strategies aim to avoid disrupting clot and diluting coagulation before hemorrhage is controlled, but the appropriate targets differ by injury pattern (for example, traumatic brain injury) and remain debated.

Seminal works

• bickell-1994
• crash2-2010
• holcomb-2015
• cannon-2018

Frequently asked questions

Why is large-volume crystalloid no longer favoured in bleeding trauma patients?

High-volume crystalloid dilutes clotting factors, can worsen hypothermia and acidosis, and may dislodge clot before bleeding is controlled; balanced blood-product resuscitation more closely replaces what is lost.

What is the lethal triad?

It is the self-reinforcing combination of hypothermia, acidosis, and coagulopathy that develops in severely bleeding patients and worsens hemorrhage and outcome.